Abstract 1420P
Background
Due to scarce publications, no specific recommendations have been published for the management of octogenarians with NSCLC. In a real-life prospective observational, multicenter study we analyze their clinical and biological characteristics, modalities of treatments by stage, overall survival (OS) and its evolution in ten years.
Methods
Between 01/01 and 12/31/2020, all patients diagnosed with a Lung Cancer (LC) in 82 participating centers, were included in a nationwide cohort (KBP-2020). Here, we report data on octogenarians with NSCLC compared to those under 80 y.o (<80). OS was calculated using the Kaplan-Meier method. Management and OS were compared to the previous cohort (KBP-2010).
Results
8,999 LC were included in KBP-2020, 1026 (11.4%) were NSCLC over 80 y-o. Median age was 83.7, 33.7% were female, 40.0% had a PS≥2 (vs 21.9% in <80), 61.2% had lost weight (mean 6.8kg) at diagnosis (vs 53.2% in <80), 32.2% were non-smokers (vs 10.8 % in <80), 62.7% had an adenocarcinoma. By stage, there were 19% localized (N=188), 18.8% locally advanced (N=186) and 62.2% metastatic (N=615) disease. Biomolecular analysis was performed in 65% of cases. Table: 1420P
Gene | EGFR | KRAS G12C | MET ex14 | BRAF V600E | HER2 | RET | ALK | ROS1 | ||||||||
N+/ N tested | % | N+/ N tested | % | N+/ N tested | % | N+/ N tested | % | N+/ N tested | % | N+/ N tested | % | N+/ N tested | % | N+/ N tested | % | |
NSCLC ≥80 y | 141/553 | 25.5 | 52/381 | 13.6 | 25/219 | 11.4 | 14/364 | 3.8 | 9/293 | 3.1 | 2/69 | 2.9 | 11/559 | 1.9 | 7/488 | 1.4 |
NSCLC <80 y | 379/3426 | 11.1 | 520/2741 | 19.0 | 39/1616 | 2.4 | 81/2553 | 3.2 | 35/2013 | 1.7 | 10/561 | 1.8 | 94/3923 | 2.4 | 61/3365 | 1.8 |
Compared to KBP-2010, in octogenarians, surgery was performed in 46.3% of localized disease (vs 26%), thoracic radiotherapy or chemotherapy in 33.3% (vs 25.5%) and 38.9% (vs 41.5%), respectively of locally advanced disease and systemic therapy was given in 55.7% of metastatic disease (vs 52.1%). Chemotherapy, targeted therapy or immunotherapy were performed in 25.4%, 18.2% and 14.9% of metastatic patients, respectively. In 2020, median OS for all NSCLC octogenarians was 8.7 months [7.0 - 9.9] vs 5.0 months [4.6 - 5.8] in 2010.
Conclusions
Compared to youngest patients, octogenarians more often had a PS≥2, lost weight, were non-smokers, had an EGFR or a MET exon 14 mutation. Compared to 2010, in 2020 surgery was performed more frequently as targeted therapy and immunotherapy while chemotherapy was less often offered resulting in better OS.
Clinical trial identification
NCT04402099.
Editorial acknowledgement
Legal entity responsible for the study
CPHG (Collège des Pneumologues des Hôpitaux Généraux).
Funding
The present study was promoted by the French College of General Hospital Pulmonologists (CPHG) with the endowment funds of Fondation du Souffle, Le Nouveau Souffle, Couleur espoir, the labeling of InCa (Institut national du Cancer) and FHF-CNR, and financial support of following laboratories: AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Chugai, Janssen, MSD, Lilly, Pfizer, Roche, Sanofi and Takeda.
Disclosure
J.B. Auliac: Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, Roche, Sanofi, Takeda; Financial Interests, Personal, Invited Speaker: BMS, Amgen, AstraZeneca, Sanofi, Boehringer. J. Pinsolle: Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Other: Pfizer. D. Debieuvre: Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Janssen, Pfizer, Ose Immunotherapeutics, Novartis, SanofiAventis, Amgen, Roche, Ipsen; Financial Interests, Personal, Invited Speaker: Gilead, Takeda, Pfizer; Financial Interests, Institutional, Funding: Roche, AstraZeneca, Janssen, MSD, Pfizer, BMS, Lilly, Boehringer Ingelheim, GSK, Chugaï, Chiesi, Novartis, Takeda, Bayer, SanofiAventis. All other authors have declared no conflicts of interest.
Resources from the same session
1411P - Tusamitamab ravtansine plus ramucirumab as 2L therapy or beyond in patients with metastatic NSq NSCLC and high CEACAM5 expression (CARMEN-LC04)
Presenter: Grace Dy
Session: Poster session 20
1412P - SAKK 17/18-ORIGIN trial: Efficacy and safety from a multicenter phase II trial of gemcitabine and atezolizumab in patients with advanced NSCLC progressing on immune checkpoint inhibitors
Presenter: Alessandra Curioni-Fontecedro
Session: Poster session 20
1414P - Impact of co-mutations on the prognosis of targeted therapy in EGFR-mutant advanced NSCLC: A result of real-world study
Presenter: Sisi Pan
Session: Poster session 20
1416P - Recurrence of infusion-related reaction (IRRs) associated to avimantamab
Presenter: Maria Virginia Sanchez Becerra
Session: Poster session 20
1417P - Change in healthcare resource use and associated costs of patients with metastatic lung cancer between 2013 and 2019: An observational study from the French national claims database
Presenter: Christos Chouaid
Session: Poster session 20
1418P - Impact of TTFields therapy on global and functional health-related quality of life (HRQoL) in metastatic non-small cell lung cancer (mNSCLC) from the pivotal LUNAR study
Presenter: Rupesh Kotecha
Session: Poster session 20
1419P - TACSTD2 (Trop-2) constitutes a promising antibody-drug conjugate target for patients with non-small cell lung cancer brain metastases
Presenter: Sara Hijazo-Pechero
Session: Poster session 20
1421P - AI-powered intracranial tumor response predicts systemic progression with high concordance in endpoint evaluation in the phase III CROWN study
Presenter: Shao-Lun Lu
Session: Poster session 20
1422P - Comprehensive genomic profiling (CGP) changes management and improves survival in patients with advanced non-small cell lung cancer (aNSCLC)
Presenter: George Simon
Session: Poster session 20